Volunteer Intake Remains Open as the Company Prepares to Post Updated Evaluation Results on Its Corporate Website in ...

In a phase 2 study, Ojemda (tovorafenib) led to responses in 43% of adults with melanoma or other solid tumors that carried rare RAF gene changes. Ojemda (tovorafenib) shrank tumors in 10 of 23 adults ...

Moderna stock has surged nearly 600% this year on a cancer vaccine trial result that almost no one outside the trial has ...

Melanoma detection is rising, but mortality isn't. Are we catching more dangerous cancers or overlabeling harmless lesions?

Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to speed up cancer vaccine ...

It's not a cure for baldness. But it might eliminate crow's feet and laugh lines by telling the tissues in your face how to ...

A three-drug combination helped treatment-resistant melanoma respond again to immune-based therapy in mouse experiments. The ...

Moderna stock gains on reports of an initiative to accelerate cancer vaccine development. Here’s why caution is warranted in ...

Doctors in Illinois and Michigan detailed a 46-year-old man with a previous history of skin cancer who bought the peptide Melanotan-II to help with his tanning. Five weeks after he started using the ...

Pills that rival biologics, weight-loss drugs paired with psoriasis treatment and a phase 3 win for a personalized mRNA ...

New details have emerged about an initiative that starts in December to fast-track the vaccines, similar to the successful ...

Some of the latest research frontiers are investigating the idea of "cancer vaccines" and other so-called targeted treatments ...